Higher Scientific Officer - Target Validation/ DNA Damage Response

31/08/2017, 23:55

Breast Cancer Research
Target Validation and DNA Damage Response
Full time
Fixed Term
1 year
£32,145 per annum inclusive
The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. We provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today, The Institute of Cancer Research (ICR) leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment. Under the leadership of our Chief Executive, Professor Paul Workman FRS, the ICR is ranked as the UK’s leading academic research centre. Together with our partner The Royal Marsden, we are rated in the top five cancer centres globally.

The Breast Cancer Now Toby Robins Research Centre at the ICR, led by Professor Andrew Tutt, is the first centre in the UK entirely devoted to breast cancer research and its goal is to advance research into the causes, diagnosis and treatment of breast cancer. Formerly known as The Breakthrough Toby Robins Breast Cancer Research Centre, at The Institute of Cancer Research, London, it is located in state-of-the-art laboratory space, with excellent core facilities and funding. The ICR is committed to attracting, developing and retaining the best minds in the world to join us in our mission – to make the discoveries that defeat cancer.

Professor Tutt is the Head of the Breast Cancer Research Division at the ICR and has interests in therapy development for BRCA1/2 associated and “triple negative” forms of breast cancer. His laboratory at Kings College London will be bringing target validation and DNA damage response projects to his new laboratory at ICR. This team will work in close partnership with that of Dr Chris Lord (Gene Function Laboratory), and with researchers in Division of Cancer Therapeutics, led by Professor Raj Chopra.

We are seeking a Higher Scientific Officer (HSO) to provide high-level technical support for a Cancer Research UK and Breast Cancer Now joint funded project, aiming to investigate role of PIM1 as a therapeutic strategy in triple-negative breast cancer (Ref: Braso-Maristany et al, 2016, PUBMED ID: 27775704). In addition, this role will also provide technical support in other projects running in the lab. The majority of these projects focus on developing novel therapeutic approaches to cancer and identifying biomarkers and relevant targets in breast cancer underlying the biology of the disease, and will include 3D cell line and organoid culture. The successful applicant will support these projects by performing molecular and cell biology techniques.

You should possess a BSc Degree (or equivalent qualification) in molecular or cellular biology and must have considerable relevant laboratory experience. Experience of molecular biology and cell culture techniques are essential, together with good organisational skills. You must also be capable of designing, implementing and independently running experiments.

Expected start date is from September 2017.

Informal enquiries can be made via email to Dr Inês Baptista (Ines.baptista@icr.ac.uk).  Please note – this address is for enquiries only and you should not send your application to this email address.

To apply please click below to submit your CV and covering letter (addressing with specific examples where you meet the person specification and incl. the names and addresses of two referees) online. 

We consider all applications on merit and have a strong commitment to enhancing the diversity of our staff.

Funded by

Breast Cancer Now
Cancer Research UK
Additional Documentation for Candidates

This Program is closed to applications.